Quick Takeaways
- BIOGEN INC. filed SCHEDULE 13D/A for Sage Therapeutics, Inc. Common Stock, par value $0.0001 per share (SAGE).
- Disclosed ownership: 10%.
- Date of event: 21 Jul 2025.
BIOGEN INC. - 21 Jul 2025 SCHEDULE 13D/A Report for Sage Therapeutics, Inc. Common Stock, par value $0.0001 per share (SAGE)
- Filing Manager
- BIOGEN INC.
- Reporting Manager
- Biogen Inc.
- Symbol
- SAGE
- Shares outstanding
- 62,414,730 shares
- Disclosed Ownership
- 6,241,473 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13D/A
- Filing time
- 21 Jul 2025, 21:18:50 UTC
- Date of event
- 21 Jul 2025
- Previous filing
- 10 Jan 2025
- Next filing
- 30 Jul 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BIOGEN INC. disclosed 10% ownership in Sage Therapeutics, Inc. Common Stock, par value $0.0001 per share (SAGE) on 21 Jul 2025."
What Changed
- Previous schedule filing date: 10 Jan 2025.
- Current filing was accepted on 21 Jul 2025, 21:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Biogen Inc. | 10% | 6,241,473 | 0 | 6,241,473 | /s/ Michael Dambach | Michael Dambach / Treasurer | 0000875045 |
| Biogen MA Inc. | 10% | 6,241,473 | 0 | 6,241,473 | /s/ Michael Dambach | Michael Dambach / Treasurer |